<code id='17B8FE3B80'></code><style id='17B8FE3B80'></style>

<acronym id='17B8FE3B80'></acronym>

<center id='17B8FE3B80'><center id='17B8FE3B80'><tfoot id='17B8FE3B80'></tfoot></center><abbr id='17B8FE3B80'><dir id='17B8FE3B80'><tfoot id='17B8FE3B80'></tfoot><noframes id='17B8FE3B80'>

<optgroup id='17B8FE3B80'><strike id='17B8FE3B80'><sup id='17B8FE3B80'></sup></strike><code id='17B8FE3B80'></code></optgroup>

<b id='17B8FE3B80'><label id='17B8FE3B80'><select id='17B8FE3B80'><dt id='17B8FE3B80'><span id='17B8FE3B80'></span></dt></select></label></b><u id='17B8FE3B80'></u>

~~<i id='17B8FE3B80'><strike id='17B8FE3B80'><tt id='17B8FE3B80'><pre id='17B8FE3B80'></pre></tt></strike></i>~~

Home» knowledge» hotspot

hotspot

hotspot

author：hotspot 2025-09-29 22:05:48 Page View：417

Alexis Borisy — Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Ventyx halts psoriasis drug development after lackluster trial results
Next article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

knowledge

Psychedelics group wrestles with new pharma identity

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Interest rates are at a 22

Interest rates are at a 22

1:10AshoppermakestheirwaythroughagrocerystoreonJuly12,2023inMiami,Florida.JoeRaedle/GettyImagesTheFe

Virginia high school admissions case could be legal follow

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Will biotech layoffs continue through 2023?

KaraColuccio,amanagingpartneratPerspectiveGroup,saysthejobmarketforbiotechexecutiveshasgottenmuchtig

read more